France has more than 8 million people suffering from obesity. In this context, the arrival on the market of the anti-obesity treatments Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly) represents new hope for patients. Because until now, if you were struggling to lose weight, your options were very limited. Some obesity specialists praise these medications for their effectiveness. Other health professionals are cautious and emphasize the lack of perspective on its long-term effects.
In this video we return to the active ingredient of these new drugs, which mimic a digestive hormone produced naturally by the human body: glucagon-like peptide-1 (GLP-1). This hormone, discovered in the 80s, acts in particular on insulin secretion and the feeling of satiety.
We also explain the conditions to qualify for this type of treatment in France, which can only be prescribed by doctors specializing in endocrinology, diabetes or nutrition. Wegogy and Mounjaro are designed to be used as second-line treatment, after failure of nutritional treatment.
To learn more about these new treatments and the excitement they are causing in the financial markets, you will find a full breakdown below.
“Understand in three minutes”
The explanatory videos that make up the “Understanding in three minutes” series are produced by the Vertical Videos department of the World. Mainly spread on platforms such as TikTok, Snapchat, Instagram and Facebook, their goal is to contextualize big events in a short format and make the news accessible to everyone.
The contributions area is reserved for subscribers.
Subscribe to access this discussion space and contribute to the discussion.
Contribute
Reuse this content
